Indication
Stage IIIA Non-small Cell Lung Cancer
8 clinical trials
5 products
7 drugs
Clinical trial
CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2025-12-01
Drug
AN0025Clinical trial
A Phase II Trial Combining Hypofractionated Radiation Boost With Conventionally-Fractionated Chemoradiation in Locally Advanced Non-small Cell Lung Cancer Not Suitable for SurgeryStatus: Active (not recruiting), Estimated PCD: 2024-07-31
Product
cisplatinDrug
etoposideClinical trial
Image-Guided Hypofractionated Radiotherapy With Stereotactic Boost and Chemotherapy for Inoperable Stage II-III Non-Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2025-01-31
Drug
carboplatinDrug
paclitaxelClinical trial
Phase II Study of FR901228 in Patients With Refractory or Progressive Small Cell or Non-Small Cell Lung CancerStatus: Completed
Product
FR901228Clinical trial
Single Cell Analysis of CXCL13+PD1+ CD8 T Cell in Association With Resistance to Pembrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLCStatus: Recruiting, Estimated PCD: 2026-04-01
Product
PembrolizumabClinical trial
A Single-Arm Phase II Study With a Safety Lead-in of Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2025-09-30
Drug
TiragolumabProduct
CarboplatinClinical trial
Retrospective Observational Study of Resectable Stage IIIA Non-small Cell Lung Cancer Patients: Pathological Response After Neoadjuvant Treatment and Patient OutcomesStatus: Recruiting, Estimated PCD: 2024-03-30
Drug
CisplatinClinical trial
A Phase II Trial of Atezolizumab Plus Induction Chemotherapy (CT) Plus Chemo-radiotherapy and Atezolizumab Maintenance Therapy in Non-resectable Stage IIIA-IIIB Non-small Cell Lung Cancer (NSCLC) PatientsStatus: Recruiting, Estimated PCD: 2026-11-15
Product
PlaclitaxelDrug
Atezolizumab